CCM
TSHA icon

CAAS Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

CAAS Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,994
Closed -$52K – 915
2022
Q4 		$52K Buy
+22,994
New +$46.6K ﹤0.01% 681
2021
Q1 		– Sell
-30,000
Closed -$796K – 1400
2020
Q4 		$796K Hold
30,000
– – 0.01% 639
2020
Q3 		$672K Buy
+30,000
New +$706K 0.02% 370

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

CAAS Capital Management's TSHA Position: Q1 2023 in Review

CAAS Capital Management sold out of Taysha Gene Therapies (TSHA) in Q1 2023, closing a stake of 22,994 shares — an estimated $52K sold.

CAAS Capital Management first reported a position in TSHA in Q3 2020 and held it in 3 quarters. The position peaked at $796K in Q4 2020. 44 funds tracked by Wall St. Rank hold TSHA as of Q1 2023.

  • CAAS Capital Management reported no remaining Taysha Gene Therapies position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 22,994 Taysha Gene Therapies shares in Q1 2023, an estimated $52K.
  • CAAS Capital Management first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 3 quarters.
  • CAAS Capital Management's Taysha Gene Therapies position peaked at $796K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.